Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial

Autor:	Ramón Corbalán, Peter Held, Mikael Dellborg, Robert F. Storey, Eugene Braunwald, Félix Medina, Eva C. Jensen, Deepak L. Bhatt, KyungAh Im, Assen Goudev, Marc P. Bonaca, Daniel Isaza, Marc Cohen, Philip E. Aylward, Giulia Magnani, Diego Ardissino, Frederic Kontny, Alexander Parkhomenko, Julia F Kuder, Marc S. Sabatine, Gabriel Steg
Rok vydání:	2015
Předmět:	Relative risk reduction Male medicine.medical_specialty Ticagrelor Adenosine Myocardial Infarction Hemorrhage Coronary Artery Disease Kaplan-Meier Estimate Drug Administration Schedule Risk Factors Internal medicine medicine Humans Myocardial infarction Renal Insufficiency Chronic Stroke Aged business.industry Coronary Thrombosis Hazard ratio Absolute risk reduction Middle Aged medicine.disease Surgery Treatment Outcome Cardiology Purinergic P2Y Receptor Antagonists Female Cardiology and Cardiovascular Medicine business Mace TIMI medicine.drug
Zdroj:	European heart journal. 37(4)
ISSN:	1522-9645
Popis:	Aims We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior myocardial infarction (MI). Methods and results Patients with a history of MI 1–3 years prior from PEGASUS-TIMI 54 were stratified based on estimated glomerular filtration rate (eGFR), with
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28507b5145357e8f431b90a29ba0307f https://pubmed.ncbi.nlm.nih.gov/26639989 Zobrazit plný text záznamu